Outsourcing Insights: Why European CMOs Are Coming to America - European contract manufacturing organizations place sales representatives in US to tap into the growing market for biopharmaceutical dev

ADVERTISEMENT

Outsourcing Insights: Why European CMOs Are Coming to America
European contract manufacturing organizations place sales representatives in US to tap into the growing market for biopharmaceutical development services


BioPharm International
Volume 20, Issue 7

LONZA CONSOLIDATING ACQUISITION

In a move impacting another biomanufacturing acquisition completed in 2007, Lonza (Basel, Switzerland) announced it will close its Baltimore, MD, development and manufacturing facility as part of a plan to consolidate its US microbial fermentation operations in Hopkinton, MA. Lonza acquired the Hopkinton and Baltimore facilities earlier this year when it acquired the biologics-based businesses of Cambrex, Inc. (East Rutherford, NJ). Lonza officials said the move will be completed in early 2008, and that much of the equipment from Baltimore will be relocated to the Hopkinton facility. Industry experts have said that the Baltimore facility was poorly designed for contract manufacturing and has never been profitable.

Lonza intends to make Hopkinton its center for microbial fermentation in North America, complementing its European center for microbial fermentation in Visp, Switzerland, where it is installing two 15,000 L fermenters. Much of that capacity has been booked by UCB Pharma to manufacture Cimzia, its new treatment for autoimmune diseases. Hopkinton will eventually have its own commercial-scale capacity, and will invest $30 million. Currently, Hopkinton has capacity up to 2800 L scale, and Baltimore has a 2000 L fermenter. An additional 250 jobs will be created at Hopkinton as a result of the expansion.

Hopkinton is within a two-hour drive of Lonza's huge cell culture manufacturing operation in Portsmouth, NH, but the facilities will run independently. The company recently began construction of a new 330,000-sq.-ft. facility in Portsmouth to further expand its cell culture capabilities there. Lonza has 93,000 L of operating capacity in Portsmouth, and is installing another 5000 L bioreactor there.

Jim Miller is president of PharmSource Information Services, Springfield, VA, 703.383.4903.,


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

NIH Launches Human Safety Study of Ebola Vaccine Candidate
August 29, 2014
Suppliers Seek to Boost Single-Use Technology
August 21, 2014
Bristol-Myers Squibb and Celgene Collaborate on Immunotherapy and Chemotherapy Combination Regimen
August 20, 2014
FDA Warns about Fraudulent Ebola Treatments
August 15, 2014
USP Awards Analytical Research
August 15, 2014
Author Guidelines
Source: BioPharm International,
Click here